Randall Grose

Dr

  • 790 Citations
  • 11 h-Index
20012018
If you made any changes in Pure these will be visible here soon.

Personal profile

Public Profile

Dr Randall Grose’s current position as the newly appointed Australian Cancer Research Foundation(ACRF) Research Fellow is to manage the day-to-day operations of the ACRF Cellular and Imaging Cytometry Core Facility . The ACRF Cellular and Imaging Cytometry Core Facility is located on level 5 North, SAHMRI and is committed to offering the highest quality service. The facility provides state of the art instrumentation, as well as technical and professional assistance to researchers within SAHMRI and SAHMRI partners, along with researchers within the City West biomedical precinct and broader South Australian Area. The Facility is fortunate to have two powerful multicolour benchtop analysers (BDFACS Canto II and LSR Fortessa X-20), a BD FACSAria™ Fusion cell sorter (with fully integrated biosafety cabinet) and a CompuCyte iCys™ Laser scanning cytometer.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2001 2018

  • 790 Citations
  • 11 h-Index
  • 21 Article
4 Citations (Scopus)

Cell banking for regulatory T cell-based therapy: Strategies to overcome the impact of cryopreservation on the Treg viability and phenotype

Gołab, K., Grose, R., Placencia, V., Wickrema, A., Solomina, J., Tibudan, M., Konsur, E., Ciepły, K., Marek-Trzonkowska, N., Trzonkowski, P., Millis, J. M., Fung, J. & Witkowski, P., 1 Jan 2018, In : Oncotarget. 9, 11, p. 9728-9740 13 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

mTORC1 plays an important role in osteoblastic regulation of B-lymphopoiesis

Martin, S. K., Fitter, S., El Khawanky, N., Grose, R., Walkley, C. R., Purton, L. E., Ruegg, M. A., Hall, M. N., Gronthos, S. & Zannettino, A., 1 Dec 2018, In : Scientific Reports. 8, 1, 14501.

Research output: Contribution to journalArticle

3 Citations (Scopus)
15 Citations (Scopus)

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

Nievergall, E., Reynolds, J., Kok, C. H., Watkins, D. B., Biondo, M., Busfield, S. J., Vairo, G., Fuller, K., Erber, W. N., Sadras, T., Grose, R., Yeung, D. T., Lopez, A. F., Hiwase, D. K., Hughes, T. P. & White, D. L., 1 Jun 2016, In : Leukemia. 30, 6, p. 1263-1272 10 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Utilization of leukapheresis and CD4 positive selection in Treg isolation and the ex-vivo expansion for a clinical application in transplantation and autoimmune disorders

Golab, K., Grose, R., Trzonkowski, P., Wickrema, A., Tibudan, M., Marek-Trzonkowska, N., Matosz, S., Solomina, J., Ostrega, D., Millis, J. M. & Witkowski, P., 2016, In : Oncotarget. 7, 48, p. 79474-79484 11 p.

Research output: Contribution to journalArticle